Christoph Rader

This inventor holds 28 USPTO granted patents and 16 published patent applications, plus 3 CIPO patents and 8 EPO patents, primarily in Antibody Engineering. Top assignees: Scripps Research Institute, The United States of America, as Represented by the Secretary, Department of Health and Human Services, University of Pennsylvania. Active years: 2001-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christoph Rader. Retrieved from https://idiyas.com/inventor/christoph-rader

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28 (Patent Applications = 16)

% Patents Active = 85.7

CIPO Patents = 3 (Patent Applications = 11)

EPO Patents = 8 (Patent Applications = 15)

Average Co-Inventor Count = 3.5

ph-index = 10

Forward Citations = 733(Granted Patents)

Location History:

San Diego, CA (US) (2001 - 2012)
Olney, MD (US) (2014 - 2016)
Jupiter, FL (US) (2015 - 2024)

Company Filing History:

13 out of 1,208

Scripps Research Institute

patents

8 out of 3,697

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

4 out of 2,659

University of Pennsylvania

patents

4. 3 out of 3,056

University of Florida Research Foundation Inc.

patents

5. 2 out of 312

H. Lee Moffitt Cancer Center and Research Institute, Inc.

University of South Florida

patents

9. 2 out of 1,045

University of Virginia Patent Foundation

patents

10. 1 out of 1

Alpha Beta Holdings, LLC

patent

11. 1 out of 309

Fred Hutchinson Cancer Center

patents

12. 1 out of 2

Modulation Therapeutics

patents

13. 3 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2026

Loading Chart...

Areas of Expertise:

Antibody Compounds

Chimeric Antigen Receptors

Catalytic Antibodies

Cancer Treatment

Cyclic Peptide Conjugates

Immunoconjugates

Humanized Antibodies

Prodrug Activation

ROR1 Antibodies

GFR Alpha-4

A33 Antigen

B Cell Reactive

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12753236 - COMPOSITIONS AND METHODS FOR TREATING CANCER (2026-10-06),

2. 12637520 - NOVEL CONJUGATION CHEMISTRY FOR CATALYTIC ANTIBODY 38C2 (2026-05-26),

3. 12286487 - Antibody compounds with reactive arginine and related antibody drug conjugates (2025-04-29),

4. 12281167 - Humanized anti-GDNF family alpha-receptor 4 (GRF-alpha-4) antibodies and chimeric antigen receptors (CARs) (2025-04-21),

5. 11970525 - Treatment of cancer using GFR alpha-4 chimeric antigen receptor (2024-04-30),

6. 11834501 - ROR2 antibody compositions and related methods (2023-12-05),

7. 11802159 - Humanized anti-GDNF family alpha-receptor 4 (GRF-alpha-4) antibodies and chimeric antigen receptors (CARs) (2023-10-31),

8. 11384139 - Antibody targeting cell surface deposited complement protein C3d and use thereof (2022-07-12),

9. 11242388 - ROR1 antibody compositions and related methods (2022-02-08),

10. 11197934 - Dual variable domain immunoconjugates and uses thereof (2021-12-14),

11. 11078273 - ROR2 antibody compositions and related methods (2021-08-03),

12. 11078235 - Cyclic peptide conjugates and methods of use (2021-08-03),

13. 10851149 - Treatment of cancer using GFR α-4 chimeric antigen receptor (2020-12-01),

14. 10618959 - ROR1 antibody compositions and related methods (2020-04-14),

15. 10035848 - Antibody targeting cell surface deposited complement protein C3d and use thereof (2018-07-31),

Title: The Innovative Journey of Christoph Rader

Introduction: Christoph Rader, a pioneering inventor based in Jupiter, FL (US), is renowned for his groundbreaking contributions to the field of biotechnology and pharmaceuticals.

Latest Patents: Christoph Rader holds several patents in the areas of targeted cancer therapies and drug delivery systems, with his most recent patent focusing on a novel approach to personalized medicine through genetic targeting.

Career Highlights: With a distinguished career spanning over two decades, Christoph Rader has held key positions in leading research institutions and biotech companies, where he has spearheaded numerous projects that have revolutionized the medical industry.

Collaborations: Throughout his career, Christoph Rader has collaborated with top scientists, researchers, and pharmaceutical companies to develop innovative solutions for complex medical challenges. His collaborative efforts have resulted in the successful development of cutting-edge therapies.

Conclusion: Christoph Rader's relentless pursuit of innovation and his passion for improving healthcare have solidified his position as a trailblazer in the field of biotechnology. His remarkable contributions continue to inspire future generations of inventors and researchers in the quest for groundbreaking medical advancements.

Profile summary based on public USPTO records.